Leukemia is a burgeoning blood cancer that forms in the bone marrow and eventually leads to the uncontrolled growth of blood cells. Amid other cancer types, Leukemia is emerging as a life impinging threat, globally. . According to the National Cancer Institute (NCI), leukemia would account for about 24.450 deaths in U.S., in 2015. Furthermore, there were 318,389 leukemia patients in the U.S. in 2012 with about 54,270 new cases anticipated in 2015. Rising incidences and high mortality rates caused by leukemia have created an indispensable need for leukemia therapeutics in the market.

While the market is regularly flooded with breakthrough treatments, there still exists an unmet medical need in the market. The leukemia therapeutics market would continue to linger in the spotlight, primarily due to rising incidences of leukemia, strong developing pipeline and targeted drug delivery. However, the limited availability of treatment and erosion by generics is likely to curtail the market growth.

The lack of early diagnosis and awareness among public are leading challenges in the market. Moreover, redefining the drug lifecycle roadmap is a major challenge for drug innovators. However, breakthrough therapy designations and accelerated approvals granted by regulatory bodies such as FDA, would provide lucrative market opportunities for the drug innovators.

Few of the key strategies adopted by leading players in the market are acquisitions and product launches. This is more evident from the acquisition of the oncology business of GlaxoSmithKline plc (GSK) by Novartis AG in late 2014. This acquisition was purely intended to expand the existing oncology drugs portfolio and develop a multi-brand repute of the acquirer.

To provide a detailed market understanding, the report segments the Leukaemia Therapeutics market on the basis of type and geography. According to the therapy type, the market is further segmented into Chemotherapy, Biological therapy, Targeted therapy, Radiation therapy and Stem cell transplant. The report covers a geographic breakdown and a detailed analysis of each of the aforesaid segments across North America, Europe, Asia Pacific, and LAMEA.

Comprehensive competitive analysis and profiles of major market players such as Novartis AG, Pfizer Inc., Sanofi, Roche Holding AG, Celgene Corporation, Bristol-Myers Squibb (BMS) and others are also provided in the report.

KEY MARKET BENEFITS:

This report provides an extensive analysis of the current and emerging market trends and dynamics in the Global Leukemia Therapeutics market.

Extensive research is done for the market by therapy type which instils a clear understanding regarding the currently used chemotherapy and targeted therapy drugs

The report covers the detailed quantitative analysis of the current market and estimations through 2014-2020, which would enable the stakeholders to capitalize on prevailing market opportunities

The leukemia therapeutics market scenario is comprehensively analysed in accordance with the key regions

Competitive intelligence highlights the business practises followed by leading market players across geographies

A detailed SWOT analysis enables to study the internal environment of the leading companies for strategy formulation

The studies evaluating competitive landscape and value chain has been taken into account in this report to help in understanding the competitive environment across the geographies

With collective industry experience of about 200 years of its analysts and experts, Allied Market Research (AMR)
encompasses most infallible research methodology for its market intelligence and industry analysis. We do not only
engrave the deepest levels of markets but also sneak through its slimmest details for the purpose of our market estimates
and forecasts. Our approach helps in building greater market consensus view for size, shape and industry trends within
each industry segment. We carefully factor in industry trends and real developments for identifying key growth factors
and future course of the market. Our research proceeds are the resultant of high quality data, expert views and analysis
and high value independent opinions. Our research process is designed to deliver balanced view of the global markets and
allow stakeholders to make informed decisions.

We offer our clients exhaustive research and analysis based on wide variety of factual inputs, which largely include interviews with industry participants, reliable statistics and regional intelligence. Our in-house industry experts play instrumental role in designing analytic tools and models, tailored to the requirements of particular industry segment. These analytical tools and models sanitize the data & statistics and enhance the accuracy of our recommendations and advice. With AMR’s calibrated research process and 360` degree data-evaluation methodology, our clients are assured of receiving:

Consistent, valuable, robust and actionable data & analysis that can easily be referenced for strategic business planning

Technologically sophisticated and reliable insights through well audited and veracious research methodology

Sovereign research proceeds that present a tangible depiction of marketplace

With a strong methodology we are, therefore, confident that our research and analysis are most reliable and guarantees sound business planning.

Secondary research
We refer a broad array of industry sources for our secondary, which typically include; however, not limited to:
Company SEC filings, annual reports, company websites, broker & financial reports and investor presentations for competitive scenario and shape of the industry

Primary research
Our primary research efforts include reaching out participants through mail, tele-conversations, referrals, professional networks and face-to-face interactions. We are also in professional corporate relations with various companies that allow us greater flexibility for reaching out industry participants and commentators for interviews and discussions, fulfilling following functions:

Validates and improves the data quality and strengthens research proceeds

Analyst tools and models
AMR has developed set of analyst tools and data models to supplement and expedite the analysis process. Corresponding to markets, where there is significant lack of information and estimates, AMR’s team of experts and analyst develop specific analyst tools and industry models to translate qualitative and quantitative industry indicators into exact industry estimates. These models also allow analysts to examine the prospects and opportunities prevailing in the market to accurately forecast the course of the market.